옵션 체인은 다양한 행사가격과 만기일에 대한 Apogee Therapeutics의 주식 옵션 주요 데이터를 보여줍니다. 트레이더들은 이 정보를 사용하여 잠재적 거래를 분석하고 Apogee Therapeutics에 대한 시장 심리를 평가합니다..

Apogee Therapeutics (NASDAQ:APGE) 주식, 옵션 체인

Apogee Therapeutics

Apogee Therapeutics Inc is a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology (I&I) indications with high unmet need. Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.

Equities

Mid Cap

News

Movers

General

APGE

CRNX

JOBY

KYMR

LNTH

PLUG

SMMT

XPEV

다음은 지난주 큰 폭의 상승세를 보인 11개의 중형주 주식이다. 이 주식들은 여러분의 포트폴리오에 있나요? 퀀텀스케이프(NYSE:QS)의 주가는 회사가 폭스바겐(Volkswagen)의 배터리 회사인 파워코(PowerCo)와 전고체 배터리 산업화 계약을 체결했다고 발표한 후 64.34% 급등했다.

샤오펑 및 퀀텀스케이프는 지난주 최고 성과를 보여준 11개 중형주 중 일부(7월 7일-7월 13일)

Apogee Therapeutics Inc

Biotech

TLSA

Tiziana Life Sciences Regains Compliance With Nasdaq

HC Wainwright &amp; Co. analyst Andrew Fein reiterates KalVista Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KALV#NASDAQ">KALV</a>) with a Buy and maintains $20 price target.

Price Target

Reiteration

Analyst Ratings

KALV

HC Wainwright & Co. Reiterates Buy on KalVista Pharma, Maintains $20 Price Target

PALI

Palisade Bio Commences Dosing In Final Cohort Of Phase 1a/b Trial Of PALI-208 In Ulcerative Colitis

Oppenheimer analyst Brian Schwartz maintains EverCommerce (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVCM#NASDAQ">EVCM</a>) with a Outperform and lowers the price target from $13 to $12.

EVCM

Oppenheimer Maintains Outperform on EverCommerce, Lowers Price Target to $12

Trade tensions between the United States and Canada are <a href="https://www.benzinga.com/news/25/03/44281882/canada-retaliates-with-20b-in-tariffs-on-us-goods-amid-trade-war">heating up</a> again, with President Donald Trump <a href="https://www.benzinga.com/25/03/44212152/mark-carney-takes-justin-trudeaus-job-as-canadas-new-pm-ready-to-face-trumps-tariff-threats-i-know-how-to-manage-crises">claiming that Canada</a> has been &#8220;ripping us off for years&#8221; with a 250% tariff on U.S. dairy products. But is this really the case? While the claim has some truth to it, the full picture is more complicated. Here&#8217;s what you need to know.
<h2 class="wp-block-heading">Canada's Dairy Tariffs Explained</h2>
Canada does impose high tariffs—sometimes as high as 298.5%—on U.S. dairy products. However, these tariffs do not apply across the board. According to fact-checking site <a href="https://www.snopes.com/fact-check/trump-canada-dairy-products-tariffs/">Snopes</a>, these rates only kick in when U.S. dairy exports exceed the quotas set under the United States-Mexico-Canada Agreement, which replaced the North American Free Trade Agreement in 2020.
Don't Miss:
<ul>
<li><a href="https://www.benzinga.com/money/qnetic-2">This 12,000 RPM Spinning Battery With Over $100 Million In LOIs Could Be The Missing Link For Green Energy — Here&#8217;s Why Early Investors Are Flocking To Invest Before Funding Closes</a></li>
<li>This data platform is reshaping how you invest in private companies —<a href="https://www.benzinga.com/money/kingscrowd-adv"> and you can be a part of it for $0.18 per share</a></li>
</ul>
Becky Rasdall Vargas, senior vice president of trade and workforce policy at the International Dairy Foods Association, clarified the issue, <a href="https://www.idfa.org/news/idfa-statement-on-potential-u-s-tariff-on-canadian-dairy-products">stating</a>: &#8220;It is accurate that Canada imposes a tariff of approximately 250% on U.S. exports of certain dairy products into Canada. However, that tariff would only apply if we were able to reach and exceed the quota on U.S. dairy exports agreed to under the U.S.-Mexico-Canada Agreement.&#8221;
So far, these quotas have never been exceeded, meaning that the higher tariff rates have not actually been applied.
<h2 class="wp-block-heading">Trump's Trade Moves and Canada's Response</h2>
Trump has prioritized trade throughout his presidency, and his most recent moves are consistent with that position. In March, he imposed a 25% tariff on imports from Canada and Mexico, though some of these tariffs were delayed until April 2. He also announced an <a href="https://www.benzinga.com/news/25/03/44253100/trump-slaps-50-tariff-on-canadian-steel-aluminum-threatens-auto-industry">additional 50% tariff</a> on Canadian steel and aluminum.
Trending: <a href="https://www.benzinga.com/money/startengine-own">The $1.3 Billion Startup Investment Boom: How This Company's Explosive Growth Is Opening Doors For Everyday Investors With A New $500 Minimum</a>
In response, Canadian Trade Minister Mary Ng called Trump's potential dairy tariffs <a href="https://www.benzinga.com/politics/25/03/44206362/canada-claps-back-at-unjustified-trump-tariffs-on-dairy-lumber">&#8220;completely unjustified&#8221;</a> and emphasized that Canada has been working to remove existing U.S. tariffs. She also defended Canada's dairy system, which is structured to protect domestic farmers through a supply-management model. This system limits imports through tariff rate quotas, allowing a certain amount of dairy to enter the country at little to no tariff before higher tariffs take effect.
<h2 class="wp-block-heading">Trade Wars and Economic Concerns</h2>
Trump&#8217;s tariff plans have raised fears about the economy more broadly than just dairy.&nbsp; Trade disputes, especially those involving lumber, have long existed between the United States and Canada. American lumber producers argue that Canada's system effectively subsidizes its industry, leading to U.S. duties on Canadian lumber ranging from 11.5% to 17.3%.
See Also: Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing —<a href="https://www.benzinga.com/money/boxabl"> this is your last chance to become an investor for $0.80 per share.</a>
Economists warn that increased tariffs could have unintended consequences. Nobel laureate Paul Krugman <a href="https://www.nytimes.com/2024/10/17/opinion/trump-tariffs-economy.html">criticized</a> Trump's trade strategy, arguing that tariffs could &#8220;shrink our economy&#8221; by making it less efficient and more costly. He added, &#8220;The effect would be to make the economy less efficient and poorer.&#8221;
<h2 class="wp-block-heading">What's Next?</h2>
The effects on both economies are still unknown as trade tensions between the U.S. and Canada continue to rise. With a <a href="https://www.benzinga.com/economics/macro-economic-events/24/11/42202496/goldman-sachs-expects-major-selloffs-in-canadian-dollar-mexican-peso-says-trump-tariffs-threaten-usmca-agreement">scheduled USMCA review in 2026</a>, dairy tariffs and Canada's supply-management system will likely remain key points of discussion. For now, while Canada does have the ability to impose high tariffs on U.S. dairy, those tariffs have never actually been applied because U.S. exports have never exceeded the agreed-upon quotas.
Read Next:
<ul>
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">Many are rushing to grab 4,000 of its pre-IPO shares for just $0.26/share!</a></li>
<li>If there was a new fund backed by Jeff Bezos offering a <a href="https://www.benzinga.com/money/arrived-private-credit-fund">7-9% target yield with monthly dividends would you invest in it</a>?</li>
</ul>

Does Canada Really Have A 250% Tariff In Place On US Dairy Products Imported Into Canada? Here Are The Facts

Oppenheimer analyst Jay Olson upgrades Nektar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKTR#NASDAQ">NKTR</a>) from Perform to Outperform and announces $6 price target.

Upgrades

NKTR

Oppenheimer Upgrades Nektar Therapeutics to Outperform, Announces $6 Price Target

Chardan Capital analyst Keay Nakae maintains ProQR Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRQR#NASDAQ">PRQR</a>) with a Buy and maintains $4 price target.

PRQR

Chardan Capital Maintains Buy on ProQR Therapeutics, Maintains $4 Price Target

A top White House representative informed crypto leaders this week that the Trump administration is eager to increase <a href="https://www.benzinga.com/markets/cryptocurrency/25/03/44258476/bitcoin-reserve-upgrades-crypto-but-paypal-ripple-stablecoins-lag-behind">its Bitcoin reserves</a> as part of a broader financial strategy.
Bo Hines, the Presidential Working Group on Digital Assets lead, shared with attendees of a confidential meeting hosted by the Bitcoin Policy Institute on Tuesday the government's intent to gather substantial Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) stocks, <a href="https://decrypt.co/309948/trump-admin-acquire-much-bitcoin-possible-white-house">according </a>to those present.
The session, following a public "Bitcoin for America" gathering, included key industry figures such as Michael Saylor of Strategy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>), Fred Thiel of Marathon Digital (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MARA#NASDAQ">MARA</a>), Nathan McCauley of Anchorage Digital, and David Bailey of Bitcoin Magazine, alongside senators Cynthia Lummis (R-Wyo.), Bill Hagerty (R-Tn.) and Bernie Moreno (R-Oh.).
When pressed on the specific amount the government might target, Hines responded with a lighthearted comparison to asking someone how many dollars they'd like, one participant relayed to Decrypt. 
A White House source later verified Hines' statement, noting that any Bitcoin purchases would be conducted without burdening taxpayers, aligning with a cost-neutral policy. 
This approach supports recent statements from senior officials advocating for additional Bitcoin acquisitions—currently around 200,000 BTC from legal confiscations—to enhance a strategic reserve established by Trump's recent directive.
Also Read: <a href="https://www.benzinga.com/news/25/03/44309155/trump-administration-focused-on-real-economy-not-market-swings-says-treasury-secretary-bessent">Trump Administration Focused On Real Economy, Not Market Swings, Says Treasury Secretary Bessent</a>
During the discussion, a question arose about the administration's stance on the Bitcoin Act, a Senate proposal reintroduced by Lummis on Tuesday, which calls for acquiring up to one million BTC, valued at about $80 billion, and legally embedding the reserve. 
Hines reportedly turned to Lummis, seated nearby, and indicated the administration favors legislation to solidify the reserve and will work to ensure its approval in Congress. 
However, a White House representative clarified to Decrypt that Hines did not back any specific bill during the event. 
The proposal's cost-neutral claim is under debate, as it suggests using Federal Reserve funds from revaluing gold certificates—last updated in 1971 and now worth over 6,800% more due to gold's rise—to finance the purchases.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/03/44304170/trump-family-in-talks-to-acquire-stake-in-binance-as-former-ceo-changpeng-zhao-pushes-for-pardon">Trump Family In Talks To Acquire Stake In Binance As Former CEO Changpeng Zhao Pushes For Pardon</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

MARA

MSTR

Trump Administration Signals Aggressive Cost-Neutral Bitcoin Accumulation Strategy

HC Wainwright &amp; Co. analyst Andrew Fein reiterates AC Immune (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACIU#NASDAQ">ACIU</a>) with a Buy and maintains $16 price target.

ACIU

HC Wainwright & Co. Reiterates Buy on AC Immune, Maintains $16 Price Target

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Baird analyst David George upgraded the rating for American Express Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AXP#NYSE">AXP</a>) from Underperform to Neutral and maintained the price target of $265. American Express shares closed at $256.43 on Thursday. <a href="https://www.benzinga.com/quote/AXP/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Raymond James analyst Ric Prentiss upgraded Crown Castle Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCI#NYSE">CCI</a>) from Outperform to Strong Buy but lowered the price target from $128 to $122. Crown Castle shares closed at $95.09 on Thursday. <a href="https://www.benzinga.com/quote/CCI/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Canaccord Genuity analyst Susan Anderson upgraded Peloton Interactive, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTON#NASDAQ">PTON</a>) from Hold to Buy and announced a $10 price target. Peloton Interactive shares closed at $6.07 on Thursday. <a href="https://www.benzinga.com/quote/PTON/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Jefferies analyst Randal Konik upgraded Revolve Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RVLV#NYSE">RVLV</a>) from Hold to Buy and announced a $30 price target. Revolve shares closed at $21.26 on Thursday. <a href="https://www.benzinga.com/quote/RVLV/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Loop Capital analyst Alton Stump upgraded the rating for Chipotle Mexican Grill, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMG#NYSE">CMG</a>) from Hold to Buy and raised the price target from $58 to $65. Chipotle shares closed at $48.73 on Thursday. <a href="https://www.benzinga.com/quote/CMG/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying AXP stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="596" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/14082741/image-124-1024x596.png" alt="" class="wp-image-824716" style="width:564px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/14082741/image-124-1024x596.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/14082741/image-124-300x175.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/14082741/image-124-768x447.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/14082741/image-124.png 1095w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/03/44324575/top-3-industrials-stocks-that-may-rocket-higher-this-month">Top 3 Industrials Stocks That May Rocket Higher This Month</a></li>
</ul>

Pre-Market Outlook

Markets

Trading Ideas

PTON

RVLV

This American Express Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Friday

Li Auto Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LI#NASDAQ">LI</a>) reported fiscal fourth-quarter 2024 revenue growth of 6.1% year-on-year to 44.3 billion Chinese yuan ($6.07 billion), missing the&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/g44323458/li-auto-inc-announces-unaudited-fourth-quarter-and-full-year-2024-financial-results" rel="noreferrer noopener">analyst consensus of 44.6 billion Chinese yuan</a>.&nbsp;
Its adjusted net earnings per ADS&nbsp;were&nbsp;3.79 Chinese yuan ($0.52), beating the&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">analyst consensus of 2.87 Chinese yuan</a>. The stock price fell after the print.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/03/44306214/gm-and-pge-team-up-to-let-evs-power-homes-offer-up-to-4500-in-energy-incentives" rel="noreferrer noopener">GM And PG&amp;E Team Up To Let EVs Power Homes, Offer Up To $4,500 In Energy Incentives</a>
Vehicle sales increased 5.6% to $5.8 billion&nbsp;due&nbsp;to increased vehicle deliveries partially offset by the lower average selling price, mainly due to different product mixes. Total vehicle deliveries were 158,696 units in the quarter,&nbsp;a 20.4% year-over-year&nbsp;increase.
The vehicle margin declined by 300 bps&nbsp;year over year&nbsp;to 19.7%, and the gross margin decreased by 320 bps&nbsp;year over year&nbsp;to 20.3%.&nbsp;
Adjusted income from operations&nbsp;was $577.6 million, up by 9.1% Y/Y. Adjusted net income decreased 12.0% Y/Y to $553.4 million.
Li Auto held cash and equivalents of $15.5 billion as of December 31, 2024, and generated $1.2 billion in operating cash flow for the quarter. Free cash flow was $830.1 million.
As of December 31, 2024, the company had 502 retail stores covering 150 cities, 478 servicing centers,&nbsp;Li Auto-authorized body and paint shops operating in 225 cities, and 1,727&nbsp;supercharging&nbsp;stations with 9,100 charging stalls.
Chair and CEO Xiang Li noted the fourth quarter propelled its full-year deliveries to surpass the 500,000 milestone, making it a leading premium automotive brand in China. Looking ahead to 2025, it plans to launch its next-generation autonomous driving architecture and new BEV models.
Q1 Outlook: Li Auto expects quarterly revenue of 23.4 billion Chinese yuan ($3.2 billion)-24.7 billion Chinese yuan ($3.4 billion), representing a <a href="https://www.benzinga.com/calendars/guidance">decrease of 8.7%–3.5% year over year.</a>
LI expects quarterly vehicle deliveries of 88,000-93,000, representing an increase of 9.5%–15.7%&nbsp;year over year.
Price Action: LI stock is down by 3.93% at $27.59 in premarket at the last check on Friday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/news/25/03/44305045/archer-taps-palantirs-ai-to-supercharge-electric-aircraft-production-and-flight-tech" target="_blank" rel="noreferrer noopener">Archer Taps Palantir&#8217;s AI to Supercharge Electric Aircraft Production and Flight Tech</a></li>
</ul>
Photo by Postmodern Studio on Shutterstock.

Earnings

Guidance

Li Auto Tops 500K Deliveries In 2024, Sees Q1 Slowdown

HC Wainwright &amp; Co. analyst Andrew Fein reiterates Arvinas (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARVN#NASDAQ">ARVN</a>) with a Buy and maintains $81 price target.

ARVN

HC Wainwright & Co. Reiterates Buy on Arvinas, Maintains $81 Price Target

Mizuho analyst Vijay Rakesh maintains NVIDIA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) with a Outperform and lowers the price target from $175 to $168.

NVDA

Mizuho Maintains Outperform on NVIDIA, Lowers Price Target to $168

On CNBC's &#8220;<a href="https://www.cnbc.com/video/2025/03/13/final-trades-visa-blackstone-eli-lilly-and-invitation-homes.html">Halftime Report Final Trades</a>,&#8221; Bryn Talkington of Requisite Capital Management said she loves Visa Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/V#NYSE">V</a>) and recommends buying the <a href="https://www.benzinga.com/quote/V/analyst-ratings">stock on the dip</a>.
The banking behemoth, on March 11, launched a new initiative aimed at tackling complex scams and preventing massive financial losses, per recent news. The company's newly formalized scam disruption practice, under its Visa Payment Ecosystem Risk and Control division, prevented over $350 million in attempted <a href="https://www.benzinga.com/25/03/44255550/whats-going-on-with-visa-stock-today">fraud in 2024 alone</a>.
Jason Snipe of Odyssey Capital Advisors said he likes Blackstone Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BX#NYSE">BX</a>), which is down 20% year-to-date.
On Feb. 27, Blackstone disclosed that Rodney Zemmel – a long-time Senior Partner at McKinsey, who served as the global leader of both McKinsey Digital and the firm&#8217;s AI Transformation initiatives – was named Global Head of Portfolio Operations.
Don't forget to check out our <a href="https://www.benzinga.com/premarket/">premarket coverage here</a>
Kevin Simpson of Capital Wealth Planning said Eli Lilly and Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) has dominated the pharma space and momentum is not slowing down beyond weight loss as it has got a pipeline of Alzheimer's, oncology and autoimmune.
On March 7, Eli Lilly released new results from Ebglyss's (lebrikizumab-lbkz) long-term study, ADjoin. New data shows Ebglyss achieved deep and sustained response for patients with moderate-to-severe atopic dermatitis (eczema) at three years.
Joshua Brown of Ritholtz Wealth Management named Invitation Homes Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/INVH#NYSE">INVH</a>) as his final trade.
Supporting his view, Mizuho analyst Haendel St. Juste, on March 13, upgraded the rating for Invitation Homes from Neutral to Outperform and increased the price target from $33 to $36.
Price Action:
<ul>
<li>Visa shares fell 1.3% to close at $328.55 on Thursday.</li>
<li>Blackstone fell 2.9% to settle at $136.53 during Thursday's session.</li>
<li>Eli Lilly declined 2.5% to close at $801.65 on Thursday.</li>
<li>Invitation Homes shares fell 0.6% to close at $32.89 on Thursday.</li>
</ul>
Check This Out: 
<ul>
<li><a href="https://www.benzinga.com/markets/25/03/44300558/jim-cramer-arthur-j-gallagher-is-solid-this-industrial-company-is-fantastic">Jim Cramer: Arthur J. Gallagher Is &#8216;Solid,&#8217; This Industrial Company Is &#8216;Fantastic&#8217;</a></li>
</ul>
Photo: Shutterstock

Long Ideas

Media

INVH

Visa, Eli Lilly, Blackstone And A Real Estate Stock On CNBC's 'Final Trades'

Barrington Research analyst Alexander Paris maintains HealthEquity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>) with a Outperform and maintains $112 price target.

Barrington Research Maintains Outperform on HealthEquity, Maintains $112 Price Target

Mizuho analyst Vijay Rakesh maintains Advanced Micro Devices (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) with a Outperform and lowers the price target from $140 to $120.

Mizuho Maintains Outperform on Advanced Micro Devices, Lowers Price Target to $120

Barrington Research analyst Alexander Paris maintains Stride (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LRN#NYSE">LRN</a>) with a Outperform and maintains $140 price target.

Barrington Research Maintains Outperform on Stride, Maintains $140 Price Target

Loop Capital analyst Alton Stump upgrades Chipotle Mexican Grill (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMG#NYSE">CMG</a>) from Hold to Buy and raises the price target from $58 to $65.

Loop Capital Upgrades Chipotle Mexican Grill to Buy, Raises Price Target to $65

WestPark Capital analyst Casey Ryan reiterates WM Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAPS#NASDAQ">MAPS</a>) with a Buy and maintains $2.61 price target.

MAPS

WestPark Capital Reiterates Buy on WM Tech, Maintains $2.61 Price Target

On CNBC's &#8220;<a href="https://www.benzinga.com/topic/mad-money-lightning-round">Mad Money Lightning Round,</a>&#8220; Jim Cramer recommended selling NANO Nuclear Energy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NNE#NASDAQ">NNE</a>).
On March 7, NANO Nuclear Energy announced that Florent Heidet, Ph.D. has joined NANO Nuclear as its Chief Technology Officer and Head of <a href="https://www.benzinga.com/quote/NNE/news">Reactor Development</a>.
Cramer said Illumina, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>) is a &#8220;challenged&#8221; company, and he doesn't really care for it.
RBC Capital analyst Conor McNamara, on March 12, maintained Illumina with an Outperform and lowered the price target from $247 to $128.
When asked about Archer Aviation Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACHR#NYSE">ACHR</a>), he said, &#8220;Keep looking but do not press the button.&#8221;
As per the recent news, Archer Aviation and Palantir Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>), on March 13, collaborated to build the AI foundation for the future of advanced aviation technologies.
The Mad Money host said he has always liked STERIS plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STE#NYSE">STE</a>) and recommended buying the stock. &#8220;I think it's just a strong company,&#8221; he added.
Supporting his view, Stephens &amp; Co. analyst Jacob Johnson, on Feb. 6, reiterated Steris with an Overweight rating and maintained a $240 price target.
Cramer said he doesn't know what Sixth Street Specialty Lending, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSLX#NYSE">TSLX</a>) really owns, so therefore he can't give his opinion on it.
RBC Capital analyst Kenneth Lee, on Feb. 26, maintained Sixth Street Specialty with an Outperform rating and raised the price target from $23 to $25.
Cramer said he likes Lam Research Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LRCX#NASDAQ">LRCX</a>) very much and recommended to own the stock.
Adding support to his choice, Susquehanna analyst Mehdi Hosseini, on Feb. 20, upgraded Lam Research from Neutral to Positive and raised the price target from $75 to $125.
Arista Networks Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ANET#NYSE">ANET</a>) has been an &#8220;amazing stock for many years,&#8221; Cramer said. He recommended buying the stock.
Supporting his view, UBS analyst David Vogt, on March 5, upgraded Arista Networks from Neutral to Buy and raised the price target from $112 to $115.
Price Action:
<ul>
<li>Illumina shares fell 0.2% to settle at $84.05 on Thursday.</li>
<li>Archer Aviation shares dipped 3.1% to close at $7.25 during the session.</li>
<li>NANO Nuclear Energy shares gained 1.9% to settle at $28.32.</li>
<li>Steris shares fell 0.9% to close at $222.45.</li>
<li>Sixth Street Specialty Lending shares fell 0.9% to close at $21.96 on Thursday.</li>
<li>Lam Research shares fell 1.7% to settle at $75.26.</li>
<li>Arista Networks shares fell 0.1% to close at $80.14 on Thursday.</li>
</ul>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/25/03/44298504/top-3-health-care-stocks-youll-regret-missing-this-quarter">Top 3 Health Care Stocks You&#8217;ll Regret Missing This Quarter</a></li>
</ul>
Image: Shutterstock

ACHR

ANET

ILMN

LRCX

PLTR

TSLX

Jim Cramer Says Illumina Is 'Challenged,' Recommends Selling This Industrial Stock

Health Care

Press Releases

Apogee Therapeutics to Host Inaugural Virtual R&D Day on December 2, 2024

Apogee Therapeutics Announces Agenda for Virtual R&D Day

Apogee Therapeutics Highlights Progress and Best-in-Class Potential of Novel Biologic Programs for I&I Diseases at 2024 Inaugural R&D Day

Apogee Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of APG333, its Novel Half-Life Extended TSLP Antibody for the Treatment of Respiratory and Broader I&I Conditions

Apogee Therapeutics to Participate at the Guggenheim SMID Cap Biotech Conference

Apogee Therapeutics Announces First Patient Dosed in Part B of Phase 2 APEX Trial of APG777 in Patients with Moderate-to-Severe Atopic Dermatitis

Apogee Therapeutics to Participate in Upcoming March Investor Conferences

Apogee Therapeutics to Host Conference Call to Report Interim Results from the Phase 1 Healthy Volunteer Trial for APG990 and Provide Combination Strategy Update on March 3, 2025

Apogee Therapeutics Announces Positive Interim Phase 1 Results from the APG990 Healthy Volunteer Trial, Unlocking Potential Maintenance Dosing Every Three and Six Months for APG279 (APG777 + APG990)

Comments

Apogee Therapeutics

Apogee Therapeutics (APGE) 옵션

Apogee Therapeutics (NASDAQ:APGE) 주식, 옵션 체인

뉴스

파트너 / 기고자

벤징가 글로벌